NasdaqCM:DRIO

Stock Analysis Report

Executive Summary

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has DarioHealth's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-12.7%

DRIO

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

-73.7%

DRIO

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: DRIO underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: DRIO underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

DRIOIndustryMarket
7 Day-12.7%1.7%2.3%
30 Day-31.2%-1.7%-1.0%
90 Day-36.3%-1.7%-0.7%
1 Year-73.7%-73.7%11.0%10.1%7.9%5.6%
3 Year-92.2%-92.2%70.4%65.2%45.6%36.3%
5 Year-96.0%-96.0%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is DarioHealth's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DarioHealth undervalued compared to its fair value and its price relative to the market?

1.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate DRIO's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate DRIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DRIO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: DRIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate DRIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DRIO is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is DarioHealth forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

10.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DRIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DRIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DRIO's revenue (40.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: DRIO's revenue (40.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if DRIO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has DarioHealth performed over the past 5 years?

-11.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DRIO is unprofitable, and losses have increased over the past 5 years at a rate of -11.9% per year.

Accelerating Growth: Unable to compare DRIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DRIO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: DRIO has a negative Return on Equity (-324.98%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DRIO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DRIO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is DarioHealth's financial position?


Financial Position Analysis

Short Term Liabilities: DRIO's short term assets ($10.8M) exceeds its short term liabilities ($5.7M)

Long Term Liabilities: DRIO's short term assets (10.8M) exceeds its long term liabilities (509.0K)


Debt to Equity History and Analysis

Debt Level: DRIO is debt free.

Reducing Debt: DRIO has not had any debt for past 5 years.


Balance Sheet

Inventory Level: DRIO has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DRIO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DRIO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DRIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of -16.3% each year


Next Steps

Dividend

What is DarioHealth's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate DRIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DRIO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DRIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of DarioHealth's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Erez Raphael (46yo)

6.2yrs

Tenure

US$1,740,127

Compensation

Mr. Erez Raphael has been the Chief Executive Officer of DarioHealth Corp. since August 09, 2013. He served as President of DarioHealth Corp. since August 09, 2013 until September 4, 2018. Mr. Raphael serv ...


CEO Compensation Analysis

Compensation vs. Market: Erez's total compensation ($USD1.74M) is about average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: Erez's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.9yrs

Average Tenure

52yo

Average Age

Experienced Management: DRIO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Age and Tenure

4.9yrs

Average Tenure

50yo

Average Age

Experienced Board: DRIO's board of directors are considered experienced (4.9 years average tenure).


Insider Trading

Insider Buying: DRIO insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$3,49028 Aug 19
Erez Raphael
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares10,000
Max PriceUS$0.35
BuyUS$5,74219 Aug 19
Yoav Shaked
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares12,888
Max PriceUS$0.45
BuyUS$4,50028 Nov 18
Allen Kamer
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,000
Max PriceUS$0.75
BuyUS$1,41026 Nov 18
Yoav Shaked
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares1,500
Max PriceUS$0.94
BuyUS$3,36021 Nov 18
Erez Raphael
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares4,000
Max PriceUS$0.84
BuyUS$1,00121 Nov 18
Yoav Shaked
EntityIndividual
Role
Chairman of the Board
Independent Chairman
Shares1,300
Max PriceUS$0.77
BuyUS$3,50021 Nov 18
Hila Karah
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$0.70

Ownership Breakdown


Management Team

  • Zvi David (58yo)

    CFO, Treasurer & Secretary

    • Tenure: 4.8yrs
    • Compensation: US$560.59k
  • JC Muyl

    Head of Commercialization North America

    • Tenure: 1.5yrs
  • Erez Raphael (46yo)

    CEO & Director

    • Tenure: 6.2yrs
    • Compensation: US$1.74m
  • Olivier Jarry (58yo)

    President & Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$177.92k
  • Shmuel Herschberg

    Marketing Director

    • Tenure: 0yrs
  • Joao Mendes-Roter

    Vice President of Marketing

    • Tenure: 1.5yrs
  • Dror Bacher (44yo)

    Chief Operating Officer

    • Tenure: 2.3yrs
    • Compensation: US$608.45k
  • Yinon Amir

    Head of Software Innovation

    • Tenure: 0yrs
  • Dov Oppenheim

    Co-Founder & Production Chief

    • Tenure: 0yrs

Board Members

  • Peter Kash (57yo)

    Member of Advisory Board

    • Tenure: 0yrs
  • Dennis McGrath (62yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$78.75k
  • Richard Stone (76yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$78.75k
  • Hila Karah (50yo)

    Independent Director

    • Tenure: 4.9yrs
    • Compensation: US$78.75k
  • Allen Kamer (48yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$65.06k
  • Erez Raphael (46yo)

    CEO & Director

    • Tenure: 6.2yrs
    • Compensation: US$1.74m
  • Yoav Shaked (47yo)

    Independent Chairman

    • Tenure: 1.3yrs
    • Compensation: US$10.25k
  • Robert Faissal (50yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Erez Levy

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Yalon Farhi (57yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$36.04k

Company Information

DarioHealth Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DarioHealth Corp.
  • Ticker: DRIO
  • Exchange: NasdaqCM
  • Founded: 2011
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$11.139m
  • Shares outstanding: 43.68m
  • Website: https://www.mydario.com

Number of Employees


Location

  • DarioHealth Corp.
  • 8 HaToKhen Street
  • Caesarea Industrial Park
  • Caesarea
  • 3088900
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DRIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2013

Biography

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:22
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.